ArticleInfluenza and other respiratory viruses2025
Seasonal Incidence of Human Metapneumovirus in High-Risk Adults With Medically Attended Acute Respiratory Illness in a Rural US Community.
Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparison of Hospitalization Costs Associated With Human Metapneumovirus and Respiratory Syncytial Virus Infection in US Adults.Open forum infectious diseases · 2026Article
- Epidemiology and Burden of Human Metapneumovirus Among Italian Adults in Outpatient and Inpatient Settings, 2014-2025.Influenza and other respiratory viruses · 2025Article
- Seasonal Incidence of Human Metapneumovirus in High-Risk Adults With Medically Attended Acute Respiratory Illness in a Rural US Community.Influenza and other respiratory viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe burden of human metapneumovirus (hMPV) among community-dwelling high-risk adults is understudied. We calculate the cumulative incidence of outpatient hMPV in high-risk adults, over five consecutive winter respiratory virus seasons (2015-2016 through 2019-2020), and describe clinical characteristics of their illnesses.
methodsWe conducted a retrospective analysis of data and respiratory specimens from adults ≥ 18 years old originally participating in a test-negative study of influenza vaccine effectiveness. We included adults with ≥ 1 high-risk condition in 2015-2016 through 2019-2020 seasons. Residual respiratory specimens were retested for hMPV using a multiplex viral panel. We calculated seasonal incidence using Poisson regression and population weighting, with the sum of observed and extrapolated hMPV cases in the study cohort divided by the number of adults with high-risk conditions in the underlying source population.
resultsWe tested 3601 respiratory samples; the mean (SD) age of individuals contributing samples was 53 (19) years. We identified 289 individuals (8.0%) with a respiratory sample positive for human metapneumovirus. The estimated seasonal incidence of outpatient hMPV-associated acute respiratory illness was 95.6 (95% CI: 80.5-113.4) cases per 10,000 high-risk adults. These values varied by season, with the highest incidence in 2015-2016 (276.8 cases per 10,000; 95% CI: 210.7-363.5) and lowest in 2016-17 (55.0 cases per 10,000; 95% CI: 31.2-97.0).
conclusionsWe identified substantial seasonal incidence of hMPV cases in community-dwelling high-risk adults in a Wisconsin population cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.